The Phosphodiesterase Inhibitors Pentoxifylline and Rolipram Suppress Macrophage Activation and Nitric Oxide Production in Vitro and in Vivo

This publication has 33 references indexed in Scilit:

• Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein
  Gene Therapy, 1999
• Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock
  Intensive Care Medicine, 1996
• The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-α and nitric oxide
  International Journal of Immunopharmacology, 1995
• Pentoxifylline Suppresses Irritant and Contact Hypersensitivity Reactions
  Journal of Investigative Dermatology, 1993
• Nitric Oxide Production by Murine Macrophages Is Inhibited by Prolonged Elevation of Cyclic AMP
  Biochemical and Biophysical Research Communications, 1993
• Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1‐ but not type 2‐associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats
  European Journal of Immunology, 1993
• Cytotoxic action of IL‐1β against pancreatic islets is mediated via nitric oxide formation and is inhibited by N^G‐monomethyl‐l‐arginine
  FEBS Letters, 1992
• Inhibition of insulin secretion by interleukin‐1β and tumour necrosis factor‐α via an L‐arginine‐dependent nitric oxide generating mechanism
  FEBS Letters, 1990
• DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water
  Analytical Biochemistry, 1990
• Immune dysfunction in diabetes-prone BB rats. Interleukin 2 production and other mitogen-induced responses are suppressed by activated macrophages.
  The Journal of Experimental Medicine, 1984